Novel Agents in Hodgkin Lymphoma

The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines

(2012) M. Lemoine et al.   BLOOD

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

(2011) T. A. Fehniger et al.   BLOOD

ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned

(2011) Simonetta Viviani et al.   NEW ENGLAND JOURNAL OF MEDICINE

HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines

(2010) Esperanza Martín-Sánchez et al.   BRITISH JOURNAL OF HAEMATOLOGY

Mechanism of action of lenalidomide in hematological malignancies

(2009) Venumadhav Kotla et al.   Journal of Hematology & Oncology

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

(2008) D. Buglio et al.   BLOOD

Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP

(2008) Stéphane Culine et al.   JOURNAL OF CLINICAL ONCOLOGY